Transthyretin Amyloidosis (ATTR)
European ATTR Amyloidosis Meeting (EU-ATTR) 2025
Congress Details
25-26 September, 2025 | ITALY
Baveno, VB, Italy
The materials in this section are intended for UK healthcare professionals and include scientific and educational congress content related to vutrisiran▼. The information contained in these presentations and posters was accurate at the time of presentation. Healthcare professionals should consult the current full Prescribing Information [for the most up-to-date information on indications, dosing, contraindications, warnings, and adverse reactions].
Congress Materials
Presentation Type
Location
Title
Associated Materials
Transthyretin Amyloidosis (ATTR)
Vutrisiran in Transthyretin Amyloidosis: A Pooled Safety Analysis of HELIOS-A and HELIOS-B
JACC: Advances
Transthyretin Amyloidosis (ATTR)
Heart Failure Society of America (HFSA) 2025
Transthyretin Amyloidosis (ATTR)
European Society of Cardiology (ESC) 2025
Transthyretin Amyloidosis (ATTR)
Realising the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis
Molecular Therapy Nucleic Acids
Transthyretin Amyloidosis (ATTR)
Heart Failure Association (HFA) 2025
Transthyretin Amyloidosis (ATTR)
